Yervoy

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical*	❑ *Home*	❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital*	❑ *Office*	❑ *Pharmacy*

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Criteria Questions:

1. What is the patient's diagnosis?
   - ❑ Cutaneous melanoma
   - ❑ Uveal melanoma
   - ❑ Central nervous system (CNS) brain metastases in patients with melanoma
   - ❑ Small cell lung cancer
   - ❑ Non-small cell lung cancer
   - ❑ Kidney cancer (including renal cell carcinoma)
   - ❑ Colorectal cancer (including small bowel adenocarcinoma, appendiceal carcinoma, anal adenocarcinoma)
   - ❑ Malignant pleural mesothelioma
   - ❑ Hepatocellular carcinoma
   - ❑ Other _____

2. What is the ICD-10 code? _____

3. Is this a request for continuation of therapy (i.e., the patient is currently being treated with the requested drug)? *If Yes, skip to Section F.* ❑ Yes ❑ No

4. How many doses of the requested drug will be given? _____ doses

5. Will the requested drug be used in any of the following regimens?
   - ❑ Single agent ❑ In combination with nivolumab
   - ❑ In combination with nivolumab and 2 cycles of platinum-doublet chemotherapy
   - ❑ Other _____

6. What is the clinical setting in which the requested drug will be used? ***Indicate ALL that apply.***
   - ❑ Adjuvant treatment
   - ❑ Advanced disease
   - ❑ Stage IV disease
   - ❑ Recurrent disease
   - ❑ Unresectable disease
   - ❑ Primary progressive disease
   - ❑ Unresectable metachronous metastases
   - ❑ Unresectable advanced disease
   - ❑ Distant metastatic disease
   - ❑ Relapsed disease
   - ❑ Metastatic disease
   - ❑ Other _____

7. What is the place in therapy in which the requested drug will be used?
   - ❑ Initial treatment ❑ First-line treatment ❑ Primary treatment ❑ Subsequent treatment
   - ❑ Other _____

Complete the following section based on the patient's diagnosis and/or Section F: Continuation of Therapy section, if applicable.

Section A: Cutaneous Melanoma

8. *If adjuvant treatment,* has the patient had a complete lymph node surgical resection or complete resection of metastatic disease? ❑ Yes ❑ No

9. Will the requested drug be used as a high-dose single agent? ❑ Yes ❑ No

Section B: Small Cell Lung Cancer

10. Has the disease relapsed within 6 months following complete or partial response or stable disease with initial treatment? ❑ Yes ❑ No

Section C: Non-Small Cell Lung Cancer

11. *If prescribed in combination with nivolumab only,* does the patient have disease with tumor mutational burden? *If Yes, no further questions.* ❑ Yes ❑ No

12. Is the disease EGFR positive? ❑ Yes ❑ No ❑ Unknown *If No or Unknown, skip to #14*

13. Has the patient received prior EGFR-targeted therapy? ❑ Yes ❑ No

14. Is the disease ALK positive? ❑ Yes ❑ No ❑ Unknown *If No or Unknown, no further questions*

15. Has the patient received prior ALK-targeted therapy? ❑ Yes ❑ No

Section D: Kidney Cancer (including Renal Cell Carcinoma)

16. Which of the following describes the risk?
    ❑ Poor risk ❑ Intermediate risk
    ❑ Favorable risk ❑ Other _____

17. What is the histology? ❑ Clear cell ❑ Non-clear cell

Section E: Colorectal Cancer

18. Is the tumor microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)?
    ACTION REQUIRED: If Yes, attach laboratory report confirming microsatellite instability-high or mismatch repair deficient tumor status. ❑ Yes ❑ No

19. Which of the following treatments has the patient received within the past 12 months?
    ❑ Adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin)
    ❑ Adjuvant CapeOX (capecitabine and oxaliplatin)
    ❑ Other _____

20. Which of the following treatments has the patient previously received?
    ❑ Oxaliplatin-based therapy ❑ Fluoropyrimidine-based therapy
    ❑ Irinotecan-based therapy ❑ Other _____

21. Has the patient previously received treatment with a checkpoint inhibitor? ❑ Yes ❑ No

Section F: Continuation of Therapy

22. Is there evidence of disease progression or unacceptable toxicity on the current regimen? ❑ Yes ❑ No

Adjuvant Treatment of Melanoma

23. Is the requested drug prescribed for the adjuvant treatment of melanoma? ❑ Yes ❑ No

24. How many months of adjuvant treatment has the patient received with the requested drug? _____ months

Cutaneous Melanoma, Kidney Cancer, Colorectal Cancer, Hepatocellular Carcinoma

25. How many doses of the requested drug has the patient already received? _____ doses

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720